Claesen, K.; Roth, L.; Mertens, J.C.; Hermans, K.; Sim, Y.; Hendriks, D.
Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced Atherosclerosis. Pharmaceutics 2021, 13, 1731.
https://doi.org/10.3390/pharmaceutics13101731
AMA Style
Claesen K, Roth L, Mertens JC, Hermans K, Sim Y, Hendriks D.
Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced Atherosclerosis. Pharmaceutics. 2021; 13(10):1731.
https://doi.org/10.3390/pharmaceutics13101731
Chicago/Turabian Style
Claesen, Karen, Lynn Roth, Joachim C. Mertens, Karlijn Hermans, Yani Sim, and Dirk Hendriks.
2021. "Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced Atherosclerosis" Pharmaceutics 13, no. 10: 1731.
https://doi.org/10.3390/pharmaceutics13101731
APA Style
Claesen, K., Roth, L., Mertens, J. C., Hermans, K., Sim, Y., & Hendriks, D.
(2021). Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced Atherosclerosis. Pharmaceutics, 13(10), 1731.
https://doi.org/10.3390/pharmaceutics13101731